Recruitment And Diversity
-
Continuing Rare Disease Treatment With A Compassionate Use Program (CUP)
10/2/2024
Learn how Rezolute successfully led its investigational drug for treating congenital hyperinsulinism (cHI) through a compassionate use program.
-
Compassionate Use Program (CUP) Benefits & Strategies In Rare Disease
10/2/2024
In part two of this series, Rezolute discusses the benefits of continuing patient care with a compassionate use program (CUP) and shares best practices for implementing one.
-
Why Diversity Of Geography Matters: A Call To Drive Rural Patient Enrollment
9/30/2024
To make clinical trials more inclusive, CROs and sponsors must intentionally expand to different — including rural — communities to recruit more diverse patients.
-
Research, Manufacturing, Regulatory, And More: What Are The Challenges With CGTs?
9/27/2024
UCB Head of U.S. Research Roger Palframan discusses the challenges with CGTs — from complex manufacturing to the need for greater and more meaningful patient engagement to evolving regulations and reimbursement.
-
Patients Get More Mileage With Free Flights To Far-Flung Clinical Trial Sites
9/20/2024
LifeLine Pilot Executive Director Lindsey Kerr shares the impact free medical flights can have on patients participating in clinical trials far from home.
-
Why Is The Reality Of Patient Engagement Not Living Up To Its Theory?
9/17/2024
Patient Co-Next's Pauline Frank discusses why pharma knows patient engagement is important but rarely succeeds in implementing it fully.
-
If Sponsors Invite Patients To See The Final Draft Protocol, It's Already Too Late
9/17/2024
Consultant Kamila Novak dives into the importance of early patient input — and why sponsors have a hard time getting it (and implementing it).
-
Why Are We Still Excluding Persons With Disabilities (PWDs) In Clinical Trials?
9/13/2024
Canary Advisors Cofounder and COO Richie Kahn details the National Council on Disability's call for the inclusion of people with disabilities in clinical trials.
-
Dedicated Trialist, Nurse Navigators Help Advance Cancer Therapy Into Accelerated Approval
9/11/2024
Thoracic medical oncologist Sally Lau, MD Lau discusses her role as a principal investigator, from the benefits of the FDA’s accelerated approval pathway to best practices for retaining a challenging patient population.
-
Pelage Embraces Diverse Patient Recruitment For Non-Hormonal Hair Loss Therapy
9/5/2024
Pelage Pharmaceuticals’ CMO Qing Yu Christina Weng, MD discusses how the company expanded criteria to include patients of all skin and hair types and incorporate decentralized elements in their trial design for a novel hair loss treatment.